Interleukin-2 (IL-2) therapies with anti-IL-2 antibodies decrease the T1DM process by enhancing CD25, CD39, and CD73 expression in regulatory T cells (Treg cells) in NOD mice (20). This evidence concerns the gene ENTPD1 and type 1 diabetes mellitus.